co-Chief Exec at Myeloma Patients Europe. Interest in health policy and medicines access plus the occasional tweet about Scotland and travel. Views mine.
Edinburgh, Scotland
Joined December 2013
- Tweets574
- Following571
- Followers482
- Likes2.7K
Kate Morgan retweeted
🤝 EHA connects hematologists to the EU policy and regulatory domain, and ensures that their needs are conveyed to decisionmakers, at the right time. The patient perspective is an important part of our message.
🔎 Curious to learn more? Read the interview with Kate Morgan, Co-CEO of @MyelomaEurope and a member of EHA’s European Affairs Committee and Patient Advocacy Committee.
🔗eha.fyi/int-kate-morgan
#EHAadvocacy #EuropeanAffairsExplained #patientadvocacy
Kate Morgan retweeted
MPE board member Snezana talks on #myeloma access in Central and Eastern Europe. “Drugs and healthcare are often looked as a cost and not an investment, which is the wrong way around - it is important for advocates to point this out to policymakers. There is a cost of inaction.”
Kate Morgan retweeted
We asked patients, carers, clinicians, researchers and stakeholders about the biggest challenges in #myeloma and how MPE can make a difference. Their insights helped shape our new Strategic Goals 2025 – 2030. These will drive our work in the coming years.
mpeurope.org/about-mpe/our-g…
Kate Morgan retweeted
We are looking for a new consultant colleague (10 PA, substantive NHS post). Great opportunity for anyone with an interest in myeloma who wants to join an academic centre. royalmarsden.nhs.uk/current-…
Kate Morgan retweeted
MPE Co-CEO, Katie Joyner, spoke at @EMN_EuMMnet's 5th annual meeting, highlighting the importance of empowering European patients to access clinical trial information.
¨Patients deserve accurate, comprehensive information for informed discussions with healthcare teams.¨
Kate Morgan retweeted
@US_FDA's Oncologic Drugs Advisory Committee (ODAC) recognises Minimal Residual Disease (MRD) as an accepted endpoint for accelerated approval in myeloma.
Read more information here: onclive.com/view/fda-s-odac-…
@OncLive
#myeloma #MRD
Kate Morgan retweeted
BREAKING: @US_FDA’s ODAC Recognizes MRD as an Accepted End Point for Accelerated Approval in Multiple Myeloma #mmsm #oncology onclive.com/view/fda-s-odac-…
Kate Morgan retweeted
Today, US FDA held an ODAC meeting to debate MRD as an endpoint to support accelerated approval in #myeloma clinical trials. Two groups (@SylvesterCancer and i2TEAMM) presented retrospective data from clinical trials that measured MRD. Final vote was 12-0 in favor.
Kate Morgan retweeted
.@EMA_News CHMP gives positive recommendation on #CART-cell therapy ciltacabtagene autoleucel in earlier lines of therapy for relapsed and refractory #myeloma
mpeurope.org/2024/02/23/ema-…
Kate Morgan retweeted
Commissioner @SKyriakidesEU highlights #EUCancerPlan progress, including the first EU network linking National Comprehensive Cancer Centres in every MS, but discussions show more work remains to tackle inequalities, among other issues.
#WorldCancerDay
Thank you to everyone who joined our #WorldCancerDay event.
We heard powerful voices, inspiring stories, and a determination to join forces to tackle cancer.
Let us continue to work hand in hand to make this difference, for our friends, our families, for all.
#EUCancerPlan
Kate Morgan retweeted
EU funded project @ASCERTAIN_EU , of which MPE is a partner, is in its second year! The Consortium meeting ended yesterday with presentations on the project’s progress, followed by discussions and suggestions from partners and advisory board members
access2meds.eu/about-ascerta…
Kicking off the new year🚀➡ASCERTAIN's third consortium meeting on January 16th and 17th📸Consortium members, stakeholders and Advisory Board representatives worked together to shape our path for the year. #healthtech #accessibility
Kate Morgan retweeted
Led by @EHA_hematology, with the involvement of MPE, the article "Guidelines for the Use and Reporting of Patient-Reported Outcomes in Multiple Myeloma Clinical Trials" is now published! An important step in improving the collection of #PROs.
mdpi.com/2072-6694/15/24/576…
Kate Morgan retweeted
@EMA_News CHMP confirms recommendation for non-renewal of Blenrep marketing authorisation.
Read more about it here: mpeurope.org/2023/12/15/ema-…
Kate Morgan retweeted
MPE is a partner in an exciting new @HorizonEU project called #CERTAINTY, which explores the role of virtual twins in CAR-T and personalised #myeloma care.
You can explore further information about the project here:
#FraunhoferIZI launches #CERTAINTY with partners, pioneering #VirtualTwin for personalised cancer care. Focused on multiple myeloma, backed by €10M EU, this collaboration is set to transform CAR-T therapy & precision medicine.
👉 izi.fraunhofer.de/en/press/p…
#InnovativeOncology
Kate Morgan retweeted
Great to see so many patient advocates presenting relevant research at the #ASH23 poster sessions. Congratulations! 1/1
@MyelomaUK @AcuteLeuk
Kate Morgan retweeted
The European Commission grants final approval for elranatamab for the treatment of relapsed or refractory #myeloma
mpeurope.org/2023/12/08/the-…
Kate Morgan retweeted
#ASH23 has already started for the MPE team! Ready to learn about the more important updates on #myeloma and #ALamyloidosis and meet friends and colleagues
The brilliant @SamanthaNier highlighting results of @AcuteLeuk #carer survey and the unmet needs for support. #ASH2023 @pfizer #advocacybreakfast
Kate Morgan retweeted
Participate in our myeloma survey on shared decision-making! Share your experiences to improve communication between patients and healthcare professionals.
Available in English, Hebrew, Slovenian, German, Spanish, French, Dutch, and Swedish
mpeurope.org/patient-evidenc…
